{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:04:06Z","timestamp":1761516246407,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.4158\/ep15713.co","type":"journal-article","created":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T17:40:48Z","timestamp":1435858848000},"page":"700-703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Commentary on the Role of Insulin Sensitizers on Cardiovascular Risk Factors in Polycystic Ovarian Syndrome: A Meta-Analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Rhoda H.","family":"Cobin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP15713.CO_bb0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4158\/EP14396.RA","article-title":"Role of insulin sensitizers on cardiovascular risk factors in polycystic ovarian syndrome: a meta-analysis","volume":"6","author":"Thethi","year":"2015","journal-title":"Endocr Pract"},{"key":"10.4158\/EP15713.CO_bb0015","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.fertnstert.2010.12.027","article-title":"Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis","volume":"95","author":"Wild","year":"2011","journal-title":"Fertil Steril"},{"key":"10.4158\/EP15713.CO_bb0020","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.fertnstert.2010.11.036","article-title":"Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and meta analysis","volume":"95","author":"Escobar-Morreale","year":"2011","journal-title":"Fertil Steril"},{"key":"10.4158\/EP15713.CO_bb0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1684\/ecn.2011.0279","article-title":"Evaluation of new adipocytokines and insulin resistance in adolescents with PCOS","volume":"22","author":"Cekmez","year":"2011","journal-title":"Eur Cytokine Netw"},{"key":"10.4158\/EP15713.CO_bb0030","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1210\/jcem.86.10.7904","article-title":"Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy","volume":"86","author":"Diamanti-Kandarakis","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP15713.CO_bb0035","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/humrep\/der159","article-title":"Vascular function in the diagnostic categories of polycystic ovary syndrome","volume":"26","author":"Moran","year":"2011","journal-title":"Human Reprod"},{"key":"10.4158\/EP15713.CO_bb0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1530\/EJE-11-0144","article-title":"Circulating platelet-derived microparticles are elevated in women with PCOS diagnosed with the 1990 criteria and correlate with serum testosterone levels","volume":"165","author":"Koiou","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP15713.CO_bb0045","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1055\/s-0031-1279740","article-title":"Insulin resistance in nonobese women with PCOS: relation to byproducts of oxidative stress","volume":"119","author":"Macut","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.4158\/EP15713.CO_bb0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/humupd\/dmq001","article-title":"Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"16","author":"Moran","year":"2010","journal-title":"Hum Reprod Update"},{"key":"10.4158\/EP15713.CO_bb0055","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1093\/humrep\/dem324","article-title":"Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome","volume":"22","author":"Luque-Ram\u00edrez","year":"2007","journal-title":"Hum Reprod"},{"key":"10.4158\/EP15713.CO_bb0060","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1210\/jc.2003-032237","article-title":"Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome","volume":"89","author":"Talbot","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP15713.CO_bb0065","doi-asserted-by":"crossref","first-page":"E868","DOI":"10.1210\/jc.2011-3357","article-title":"Relative contributions of oligomenorrhea and hyperandrogenemia to the risk of metabolic syndrome in midlife women","volume":"97","author":"Polotsky","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP15713.CO_bb0070","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/humupd\/dmr001","article-title":"PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and metaanalysis","volume":"17","author":"de Groot","year":"2011","journal-title":"Hum Reprod Update"},{"key":"10.4158\/EP15713.CO_bb0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2265.2007.03145.x","article-title":"The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome","volume":"69","author":"Amato","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP15713.CO_bb0080","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1210\/jc.2005-1329","article-title":"Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome","volume":"91","author":"Ehrmann","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP15713.CO_bb0085","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.fertnstert.2010.02.015","article-title":"Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypes","volume":"94","author":"Wiltgen","year":"2010","journal-title":"Fertil Steril"},{"key":"10.4158\/EP15713.CO_bb0090","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/humrep\/des232","article-title":"Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria","volume":"27","author":"Yildiz","year":"2012","journal-title":"Hum Reprod"},{"key":"10.4158\/EP15713.CO_bb0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2265.2011.04015.x","article-title":"Polycystic ovary syndrome is associated with atherogenic changes in lipoprotein particle number and size independent of body weight","volume":"75","author":"Sidhwani","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP15713.CO_bb0100","doi-asserted-by":"crossref","DOI":"10.2174\/1567201812666150120163025","article-title":"Excess metabolic and cardiovascular risk is not manifested in all phenotypes of polycystic ovary syndrome: implications for diagnosis and treatment","author":"Daskalopoulos","year":"2015","journal-title":"Curr Vasc Pharmacol"},{"key":"10.4158\/EP15713.CO_bb0105","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.fertnstert.2014.08.001","article-title":"Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?","volume":"102","author":"Daan","year":"2014","journal-title":"Fertil Steril"},{"key":"10.4158\/EP15713.CO_bb0110","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1210\/jc.2011-1609","article-title":"Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls","volume":"96","author":"Lass","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP15713.CO_bb0115","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1210\/jc.2005-1490","article-title":"The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery","volume":"90","author":"Escobar-Morreale","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP15713.CO_bb0120","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/humupd\/dmq045","article-title":"Exercise therapy in polycystic ovary syndrome: a systematic review","volume":"17","author":"Harrison","year":"2011","journal-title":"Hum Reprod Update"},{"key":"10.4158\/EP15713.CO_bb0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1258\/acb.2011.011071","article-title":"Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study","volume":"49","author":"Sathyapalan","year":"2012","journal-title":"Ann Clin Biochem"},{"key":"10.4158\/EP15713.CO_bb0130","first-page":"905","article-title":"Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance","volume":"35","author":"Celik","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/EP15713.CO_bb0135","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jacc.2011.09.067","article-title":"Meta-analysis of statin effects in women versus men","volume":"59","author":"Kostis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/EP15713.CO_bb0140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrendo.2014.102","article-title":"The management of patients with polycystic ovary syndrome","volume":"10","author":"Jayasena","year":"2014","journal-title":"Nat Rev Endocrinol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20356780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20356780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:59:16Z","timestamp":1761515956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20356780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1530891X20356780"],"URL":"https:\/\/doi.org\/10.4158\/ep15713.co","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Commentary on the Role of Insulin Sensitizers on Cardiovascular Risk Factors in Polycystic Ovarian Syndrome: A Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP15713.CO","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}